A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg

NCT02091986 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

882

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: Symbicort pMDI
DRUG: Symbicort pMDI
OTHER: Budesonide pMDI

Sponsor

AstraZeneca